 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...156157158159160161162163164165166...208209» |
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Checkpoint inhibition: A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). (clinicaltrials.gov) - Apr 1, 2021
P2, N=40, Recruiting, Sponsor: Hunan Cancer Hospital
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC (clinicaltrials.gov) - Apr 1, 2021
P2, N=53, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group
Retrospective data, Journal, Monotherapy: Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study. (Pubmed Central) - Mar 31, 2021
Apatinib can improve the disease control rate of recurrent and metastatic cervical cancer when chemotherapy has failed, and the treatment is well tolerated. This represents that apatinib may be a new treatment option for metastatic cervical cancer patients.
- || AiTan (rivoceranib) / HLB Bio Group
PK/PD data, Preclinical, Journal: Pharmacokinetic interaction between a Chinese herbal formula Huosu Yangwei oral liquid and apatinib in vitro and in vivo. (Pubmed Central) - Mar 30, 2021
This represents that apatinib may be a new treatment option for metastatic cervical cancer patients. Huosu Yangwei oral liquid could inhibit mammalian CYPs and modulated the metabolic half-life of apatinib both in vitro and in vivo.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Hyaluronic acid reduction-sensitive polymeric micelles achieving co-delivery of tumor-targeting paclitaxel/apatinib effectively reverse cancer multidrug resistance. (Pubmed Central) - Mar 30, 2021
Released APA effectively inhibited the function of the P-glycoprotein (P-gp) drug pump and improved the sensitivity of MDR cells to chemotherapeutic agents, leading to the recovery of PTX chemosensitivity in MDR cells. As expected, this newly developed intelligent drug delivery system could effectively control MDR, both in vitro and in vivo.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, PK/PD data, Journal: Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors. (Pubmed Central) - Mar 30, 2021
Concomitant apatinib administration resulted in significant increases in systemic exposure to nifedipine and S-warfarin. Owing to the risk of pharmacokinetic drug-drug interactions based on CYP3A4/CYP2C9 inhibition by apatinib, caution is advised in the concurrent use of apatinib with either CYP2C9 or CYP3A4 substrates.
- || Clinical, Journal: Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience. (Pubmed Central) - Mar 30, 2021
Grade 3/4 adverse events occurred in 6 (23.1%) patients and were manageable. Our findings suggest that multi-targeted TKI rechallenge may provide potential clinical benefits for patients with advanced soft tissue sarcoma after their previous TKI treatment.
- ||||| AiRuiKa (camrelizumab) / Incyte
Biomarker: #ELCC21 Great discussn of IO proferred papers by @JulieBrahmer: - camrelizumab/chemo: a new potential std in China for 1L sq nsclc - unique Tox profile of this agent: skin tox (RCCEP) - 3yr OS KN047 ~30% - TMB: IO/IO/chemo biomarker of PFS&ORR, trend for OS @OncoAlert #LCSM (Twitter) - Mar 28, 2021
- ||||| AiRuiKa (camrelizumab) / Incyte
Biomarker: #ELCC21 Great discussn of IO proferred papers by @JulieBrahmer: - camrelizumab is a new potential std in China for 1L sq nsclc - unique Tox profile of this agent: skin tox (RCCEP) - 3yr OS data KN047 - TMB is an IO/IO/chemo biomarker of PFS&ORR, trend for OS @OncoAlert #LCSM (Twitter) - Mar 28, 2021
- ||||| AiRuiKa (camrelizumab) / Incyte
#ELCC21 CameL study: Camrelizumab + chemo v chemo alone in 1L sq nsclc (proferred paper) shows: - HR 0.37 for PFS (primary endpt, did control arm underperform?) - HR 0.55 for OS - similar Tox profile to other anti-PD1 @OncoAlert #LCSM (Twitter) - Mar 27, 2021
- ||||| AiRuiKa (camrelizumab) / Incyte
Clinical, Adverse events: #ELCC21 Camrelizumab had a very high rate of immune related adverse events (77%!) but 63% was RCEP (reactive capillary endothelial proliferation). See description in slide from #ESMO18 - common with camrelizumab, correlates with efficacy, reversible. @OncoAlert (Twitter) - Mar 26, 2021
- |||| AiRuiKa (camrelizumab) / Incyte
#ELCC21 Addition of camrelizumab also improved survival. Median OS not reached vs 14.5m for HR 0.55 - median f/u for OS here 13.5m. RR favored IO combination (65% vs 37%) and duration of response 13.1m with camrelizumab/chemo vs 4.4m with chemo alone. @OncoAlert #LCSM (Twitter) - Mar 26, 2021
- ||||| AiRuiKa (camrelizumab) / Incyte
#ELCC21 The addition of camrelizumab to carbo/pac significantly improved PFS (primary endpoint) with median PFS 8.5m (from 4.9m), HR 0.37. Benefit seen across PDL1 strata (HR 0.30 in PDL1 high, 0.49 in PDL1 negative). @OncoAlert #LCSM (Twitter) - Mar 26, 2021
- ||||| AiRuiKa (camrelizumab) / Incyte
Clinical: #ELCC21 Design for CameL-sq is straightforward with carbo/pac and 1:1 randomization to camrelizumab or placebo x 2y (crossover included), PFS primary endpoint. Note doses here: carbo AUC 5 and paclitaxel 175mg/m2, lower than used in KN407 and much better tolerated IMO. @OncoAlert (Twitter) - Mar 26, 2021
- |||||| AiRuiKa (camrelizumab) / Incyte
Clinical, P3 data: #ELCC21 Dr. Caicun Zhou presents results from CameL-sq: randomized phase III of carboplatin, paclitaxel and camrelizumab/placebo in metastatic squamous NSCLC. Camrelizumab is an anti-PD1 antibody with approval in China for Hodgkins lymphoma. @OncoAlert #LCSM (Twitter) - Mar 26, 2021
- |||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC (clinicaltrials.gov) - Mar 26, 2021
P3, N=456, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Our findings suggest that multi-targeted TKI rechallenge may provide potential clinical benefits for patients with advanced soft tissue sarcoma after their previous TKI treatment. Not yet recruiting --> Recruiting
- ||||||| NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Trial completion: Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study) (clinicaltrials.gov) - Mar 26, 2021
P3, N=599, Completed, Sponsor: Bausch & Lomb Incorporated
Not yet recruiting --> Recruiting Recruiting --> Completed
- || AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib. (Pubmed Central) - Mar 26, 2021
Nomograms were developed from clinical features and nutritional indicators to predict the probability of achieving 3-month and 4-month PFS and 7-month and 8-month OS with antiangiogenic therapy for advanced lung cancer. Dynamic changes in body composition before the initiation of treatment contributed to early detection of poor outcome.
- |||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial: HORIZON-Lung: A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2021
P1/2, N=120, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical data, Retrospective data, Journal, Real-world evidence: Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study. (Pubmed Central) - Mar 24, 2021
The administration with apatinib for patients with chemotherapy-refractory ES-SCLC was of potential clinical significance. The clinical outcomes of patients with ES-SCLC who were treated with apatinib could be impacted by VEGFR2 889C>T polymorphism through mediating the VEGFR2 mRNA expression.
- | AiTan (rivoceranib) / HLB Bio Group
New trial: Glioblastoma Response Prediction to Apatinib (clinicaltrials.gov) - Mar 23, 2021
P, N=18, Not yet recruiting, Sponsor: Beijing Sanbo Brain Hospital
- |||| imrecoxib/tramadol (HR18042) / Jiangsu Hengrui Pharma
New P2 trial: A Study to Evaluate the Efficacy and Safety of HR18042 Tablets in the Treatment of Postoperative Pain of Impacted Tooth. (clinicaltrials.gov) - Mar 23, 2021
P2, N=187, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer (clinicaltrials.gov) - Mar 23, 2021
P2, N=39, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | plinabulin (BPI 2358) / BeyondSpring
Journal: Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. (Pubmed Central) - Mar 23, 2021
Importantly, plinabulin induced a functional M1-like polarization of tumor infiltrating macrophages in murine tumors as well as in tumor samples from ovarian cancer patients, by preferentially triggering M1 proliferation. Our study uncovers a novel immunomodulatory effect of plinabulin in directly triggering M1 polarization and proliferation as well as promoting TAM anti-tumoral effector functions.
- |||| HR021618 / Jiangsu Hengrui Pharma
New P2 trial: HR021618 in Moderate to Severe Pain After Abdominal Surgery (clinicaltrials.gov) - Mar 22, 2021
P2, N=60, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Avastin (bevacizumab) / Roche
New P2 trial: Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy (clinicaltrials.gov) - Mar 22, 2021
P2, N=20, Not yet recruiting, Sponsor: Women's Hospital School Of Medicine Zhejiang University
- |||| SHR-1603 / Jiangsu Hengrui Pharma
Trial suspension, First-in-human: Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Mar 21, 2021
P1, N=128, Suspended, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Our study uncovers a novel immunomodulatory effect of plinabulin in directly triggering M1 polarization and proliferation as well as promoting TAM anti-tumoral effector functions. Not yet recruiting --> Suspended
- || AiTan (rivoceranib) / HLB Bio Group
Does Apatinib have any advantage over Bev, other than being oral? (Twitter) - Mar 21, 2021
- |||||| AiRuiKa (camrelizumab) / Incyte
Clinical: Interesting data from CLAP study of camrelizumab in #cervicalcancer indicate better survival in pts with PIK3CA and PTEN aberrations. #SGOMtg #gyncsm (Twitter) - Mar 20, 2021
- | AiTan (rivoceranib) / HLB Bio Group
Journal: IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma. (Pubmed Central) - Mar 19, 2021
Not yet recruiting --> Suspended IL-17 had a pivotal role in the invasion and angiogenesis of HCC and contribute to the selection of patients who may benefit from adjuvant TACE combined with apatinib.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer. (Pubmed Central) - Mar 19, 2021
The FLOTA regimen can achieve better perioperative efficacy and acceptable toxicity compared with that of the FLOT regimen in neoadjuvant treatment of LAGC. The FLOTA regimen for neoadjuvant therapy for LAGC merits further study.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Clinical data, Review, Journal, PD(L)-1 Biomarker, IO biomarker: Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. (Pubmed Central) - Mar 19, 2021
Thus, tumor immunotherapy using PD-1/PD-L1 blockers exhibits promising outcomes for the treatment of HCC, and more novel PD-1/PD-L1 inhibitors are being developed to fight against this disease. The present review discusses the clinical results and influencing factors of PD-1/PD-L1 inhibitors in HCC to provide insight into the development and optimization of PD-1/PD-L1 inhibitors in the treatment of HCC.
- ||| Irene (pyrotinib) / Jiangsu Hengrui Medicine
And lastly, most data targeting HER2 in lung cancer is for HER2 Ex20 ins mutations. This is an Exon 19 point mutation. It appears to be activating, maybe resistant to lapatinib, but there is data (n=1) of response to pyrotinib. https://t.co/M30KIcNO9P (Twitter) - Mar 19, 2021
- |||| Stivarga (regorafenib) / Bayer
New P2 trial: Carelizumab Combined With Regorafenib in the Treatment of HCC?CARE-2020? (clinicaltrials.gov) - Mar 19, 2021
P2, N=69, Not yet recruiting, Sponsor: Nanfang Hospital of Southern Medical University
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine, poziotinib (HM 78136B) / Spectrum Pharma, Hanmi, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Very hopeful outlook for your pt. given (1) Enhertu; (2)poziotinib [via (a) pozi Cohort 7 post plat and BID or (b) via Spectrum EAP post Enhertu &/or post mobo]; (3) mobo (I hope a mobo HER2 EAP could materialize by the time your pt needs it); & 4) perhaps pyrotinib EAP later. (Twitter) - Mar 18, 2021
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion date, Trial suspension, Trial primary completion date: Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 18, 2021
P2, N=50, Suspended, Sponsor: Peking University
The present review discusses the clinical results and influencing factors of PD-1/PD-L1 inhibitors in HCC to provide insight into the development and optimization of PD-1/PD-L1 inhibitors in the treatment of HCC. Trial completion date: Jun 2020 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Dec 2019 --> Dec 2022
- || AiTan (rivoceranib) / HLB Bio Group
Trial completion: Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 18, 2021
P1, N=12, Completed, Sponsor: Peking University
Trial completion date: Jun 2020 --> Dec 2022 | Recruiting --> Suspended | Trial primary completion date: Dec 2019 --> Dec 2022 Recruiting --> Completed
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine
Review, Journal: The Role of ERBB2/HER2 Tyrosine Kinase Receptor in the Regulation of Cell Death. (Pubmed Central) - Mar 18, 2021
In addition to the activation of molecular pathways responsible for cell proliferation and survival under stress conditions, HER2 directly regulates programmed cell death. Here, we review the studies focused on the involvement of HER2 in various signaling pathways and its role in the regulation of apoptosis.
- ||| AiRuiKa (camrelizumab) / Incyte
Clinical, P3 data, Journal: Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. (Pubmed Central) - Mar 18, 2021
P3
The primary endpoint was met at the interim analysis, showing a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in all patients, supporting camrelizumab plus carboplatin and pemetrexed as a first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations. The trial is being continued to collect long-term outcomes in all patients and carry out confirmatory statistical testing for progression-free survival in the PD-L1-positive population.
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer (clinicaltrials.gov) - Mar 17, 2021
P2, N=60, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Irene (pyrotinib) / Jiangsu Hengrui Medicine
Journal: Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib. (Pubmed Central) - Mar 17, 2021
Our results indicated that pyrotinib sensitivitied HER2 positive esophageal cancer cells to radiation treatment through various mechanisms. These findings may provide a new therapeutic strategy for treating HER2 positive esophageal cancer.
- || AiRuiKa (camrelizumab) / Incyte
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication. (Pubmed Central) - Mar 17, 2021
Administration of immune checkpoint inhibitor monotherapy in this subgroup of patients harboring EGFR kinase domain duplication should be performed with caution. These results need to be further confirmed in a larger cohort of patients.
- || AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal: Long-term response with low-dose of apatinib combined with S-1 in pretreated patient with advanced squamous cell lung cancer: A case report. (Pubmed Central) - Mar 17, 2021
This case indicated that low-dose apatinib combined with S-1 might be effective and safe in selected pretreated patients with advanced squamous cell lung cancer. It might be worthy to conduct further researches to investigate the efficacy and safety of the combination therapy in such patients.
- ||| SHR2150 / Jiangsu Hengrui Pharma
New P1 trial: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ?Pharmacodynamics of Oral SHR2150 in Healthy Subjects (clinicaltrials.gov) - Mar 17, 2021
P1, N=62, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2/3 trial, Circulating tumor DNA: Artemis: A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (clinicaltrials.gov) - Mar 16, 2021
P2/3, N=260, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial termination: A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC (clinicaltrials.gov) - Mar 16, 2021
P2, N=5, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
It might be worthy to conduct further researches to investigate the efficacy and safety of the combination therapy in such patients. N=50 --> 5 | Not yet recruiting --> Terminated; changes in the R&D strategy
- || SHR-1702 / Jiangsu Hengrui Pharma
Enrollment open, Monotherapy: A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Mar 16, 2021
P1, N=42, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=50 --> 5 | Not yet recruiting --> Terminated; changes in the R&D strategy Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Platinum resistant: Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Mar 16, 2021
P2, N=28, Recruiting, Sponsor: Peking Union Medical College Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: H3K27M mutant diffuse midline glioma: a case report. (Pubmed Central) - Mar 16, 2021
Its pathological classification is diverse, imaging features lack specificity, and prognostic factors are complex. Traditional radiochemotherapy has limited effects, molecular targeted therapy, especially intervention of epigenetic regulation is being explored.
- ||| Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Clinical, P3 data, Journal: Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. (Pubmed Central) - Mar 16, 2021
P3
Traditional radiochemotherapy has limited effects, molecular targeted therapy, especially intervention of epigenetic regulation is being explored. Pyrotinib plus capecitabine significantly improved progression-free survival compared with that for lapatinib plus capecitabine, with manageable toxicity, and can be considered an alternative treatment option for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy.